Pfizer teams with Cytos to develop new vaccines

Further bolstering its ambitious vaccine program, Pfizer has teamed up with Cytos Biotechnology to develop, manufacture and commercialize vaccines for a defined number of human diseases. Cytos gains CHF 10 million up-front and up to CHF 140 in possible additional milestones. The company could also score research funding and royalties on any products that make it to market. The deal incorporates specific disease targets which are outside the scope of Cytos' own programs.

--read the report in FierceBiotech

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.